Helsepersonell

Committed to helping you meet the evolving challenges and opportunities in patient care.

Helsepersonell

  • Providing innovative therapies and technologies to help you treat patients with life-threatening illnesses in the ICU.

  • From the pharmacy to the bedside, we help you maximize safety, streamline processes and build cost efficiency throughout the hospital.

  • Nutritional Care

    Acute and chronic nutritional care for your patients who are unable to get adequate nutrients orally or enterally.

  • Pioneering innovation in hemodialysis and peritoneal dialysis to help you achieve better outcomes for your patients.

  • Surgical Care

    Delivering innovative surgical products that help you operate with confidence, precision and speed.

  • Our portfolio of acute, nutritional, renal, hospital and surgical care products helps advance healthcare around the world.

Perspektiv

For more than 85-years, we have worked at the intersection of saving and sustaining lives.

Perspektiv

Our Story

Our more than 85-year heritage gives us distinct perspective on the needs of patients and caregivers. We lead today by putting those insights to work to deliver new, better healthcare solutions and access to care in the communities where we live and work.

Our Story
  • Our Governance

    We are proud of our strong commitment to maintaining the highest standards of corporate governance.

  • Fueling Collaborative Innovation

    Nurturing a culture of innovation is critical to delivering on our mission to save and sustain lives. We partner with the healthcare community to continually find more efficient, smarter ways to help solve the world's most pressing healthcare challenges.

  • We are committed to doing business the right way, ensuring that we champion our employees, our communities, our customers and patients, and our environment in everything we do.

  • Inclusion & Diversity

    We are committed to attracting, motivating and retaining an inclusive and diverse workforce.

  • Our History

    For more than 85 years, we’ve been focused on saving and sustaining lives and elevating patient care.

Pasienter

Helping you reach a healthy life, full of possibility.

Pasienter
  • Critical Care

    When every moment counts, our therapies help healthcare specialists provide life-sustaining treatment to you or your loved one.

  • Hospital Care

    From the pharmacy to the bedside, we support you and your healthcare providers with IV medications and infusion technologies designed with safety in mind.

  • When medical conditions prevent you from adequately feeding yourself, we provide life-saving clinical nutrition options to help you regain or maintain your health.

  • Renal Care

    Chronic kidney disease (CKD) is an ongoing journey. While every journey is unique, Baxter is with you every step of the way, providing options to meet your lifestyle needs.

  • Surgical Care

    We partner with surgical teams around the world so they can operate with confidence, precision and speed for a successful outcome to your surgery.

Baxter Appoints Dr. David Wilkes to Its Board and Albert Stroucken as Lead Independent Director

Press Release

  • Addition of Dr. Wilkes complements and expands current board expertise

  • Mr. Stroucken's appointment reflects ongoing board refreshment efforts

DEERFIELD, Ill. -

Baxter International Inc. (NYSE:BAX), a leading global medical products company, today announced it has appointed David S. Wilkes, M.D., dean, University of Virginia School of Medicine, and co-founder and chief scientific officer of biotech start-up ImmuneWorks Inc., to its board of directors. Dr. Wilkes will serve on Baxter's Quality, Compliance and Technology Committee. Additionally, Baxter has appointed Albert P.L. Stroucken, former executive chairman and chief executive officer, Owens-Illinois, Inc., and a Baxter director since 2004, as its lead independent director. Mr. Stroucken, who previously served as the chairman of the Audit Committee, will succeed Thomas T. Stallkamp, who has served as lead independent director from May 2014 to February 2021. Mr. Stallkamp will continue to serve as a director of the board. Both new appointments are effective today and will bring the total number of directors serving the company to 13.    

“We are pleased to welcome Dr. Wilkes to Baxter's board,” said José (Joe) E. Almeida, chairman and chief executive officer. "His deep medical and research expertise, track record as a transformational leader, and distinguished career as an internationally recognized biotech entrepreneur will enhance and further diversify our current board membership. I'm confident his patient-centric approach and contributions will advance our Mission to save and sustain lives."

Added Mr. Almeida, "We extend our gratitude to Al for assuming the role as our new lead independent director. His experience as a former CEO and chair of Baxter's Audit Committee makes him uniquely suited to lead our board and provide management oversight. We also want to recognize Tom for his years of leadership and service as our lead independent director; his deep understanding of our business and the independence with which he has advanced this role have delivered tremendous value to Baxter and our stakeholders. We look forward to Tom's continued contributions to the board."

David S. Wilkes, M.D. 

Dr. Wilkes currently serves as dean of the University of Virginia School of Medicine, where he has led the medical school's transformation, which has included targeted initiatives to improve funding and research endeavors as well as diversity programs. He is also co-founder and chief scientific officer of ImmuneWorks Inc., a biotech company developing novel therapeutics for immune-mediated lung diseases; and the national director of the Harold Amos Medical Faculty Program for the Robert Wood Johnson Foundation, one of the nation’s leading programs in training physician scientists. Prior to these roles, Dr. Wilkes served in positions of increasing responsibility at Indiana University School of Medicine, where he focused on medical research. He received his bachelor's degree in biology from Villanova University, his medical degree from Temple University School of Medicine, and conducted his residency at Temple University Hospital. Dr. Wilkes completed a post-doctoral fellowship in pulmonary and critical care at University of Texas Southwestern Medical. He is also a military veteran, having served three years as a major in the U.S. Air Force Medical Corps. In 2020, Dr. Wilkes was elected to the prestigious National Academy of Medicine, one of the highest honors in the fields of health and medicine. 

Albert P.L. Stroucken

Mr. Stroucken is former executive chairman of the board of directors of Owens-Illinois, Inc., where he also served as chairman, president and chief executive officer. Mr. Stroucken previously served as chairman, president and chief executive officer of H.B. Fuller Company, a manufacturer of adhesives, sealants, coatings, paints and other specialty chemicals. Prior to these positions, he held roles of increasing responsibility at Bayer AG and Bayer Corporation. Mr. Stroucken previously served as a director of Baxalta Incorporated and as a director of Shire plc until its acquisition by Takeda Pharmaceutical Company Limited in January 2019.

About Baxter 

Every day, millions of patients and caregivers rely on Baxter’s leading portfolio of critical care, nutrition, renal, hospital and surgical products. For more than 85 years, we’ve been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers that make it happen. With products, technologies and therapies available in more than 100 countries, Baxter’s employees worldwide are now building upon the company's rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit www.baxter.com and follow us on Twitter, LinkedIn and Facebook.

Baxter is a registered trademark of Baxter International Inc.